Optimized Tandem CAR T-Cell Therapy Targeted CD19/CD20 Appears Feasible in B-NHL – Targeted Oncology

Optimized tandem CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy induced potent and durable anti-tumor responses as treatment of patients with relapsed/refractory B cell non-Hodgkin lymphoma (B-NHL) with good control of cytokine release syndrome (CRS) and CAR T-related encephalopathy syndrome, according to a phase 1/2 clinical trial presented in a poster at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

After a median of 13.5 months of follow-up (IQR, 33.2-3.3), 84% of patients had an objective response, and 74% had a complete response (CR). The duration of overall response rate (ORR) at 6 months was 94% and 74% at 12 months.

Both the median progression-free and overall survivals had not been reached for patients at the time of data cut-off. At 6 months, the progression-free survival rate was 76%, and at 12 months, it was 59%.

Sixty-two patients experienced CRS (71%), which was grade 1 or 2 in 61% of patients and grade 3 or greater in 10%. The median time to the onset of CRS after infusion was 1 day (range, 1-5). The median duration of CRS was 6 days (range, 1-9). Investigators also noted that the median time to the onset of grade 3 CRS was 1 day (range, 1-2).

The most common adverse events within 1 month of the IV infusion were leukopenia, pyrexia, and anorexia. Only 2 patients (2%) experienced CAR T-cell-related encephalopathy syndrome of grade 3 severity.

Three treatment-related deaths occurred in the study, 2 due to pulmonary infection and 1 due to deposition of CAR T cells in pulmonary alveoli.

Ninety-nine patients were screened for the study, of which 87 received the infusion and 74 were followed for at least 3 months before the data cutoff date. Patients underwent leukapheresis and conditioning chemotherapy, which was followed by a single intravenous infusion of tandem CD19/20 CAR T cells on day 0 at a dose of 0.5x106x106 per kg of body weight.

The majority of patients in the study were under the age of 60 years (82%) and female (53%). Overall, 62% of patients had an ECOG performance status of 0 or 1 versus 38% who had a 2. Upon study entry, 85% had stage III or IV disease and 15% had stage I or II. Patients were diagnosed with either diffuse large B-cell lymphoma (66%), follicular lymphoma (15%), transformed follicular lymphoma (7%), primary mediastinal B-cell lymphoma (6%) or other (6%).

Fifty-six percent of patients had 3 to 5 prior lines of anti-neoplastic therapy, while 27% had 2 or less and 17% had 6 or more. The majority of patients had a lesion diameter less than 10 cm (78%) and had tumor burden SPD of 100 cm2 or more (55%). Eighty percent of the patients were refractory, 20% had relapsed to second-line or later therapy, 14% became refractory after stem cell transplant, and 10% had relapsed after a prior CD19 CAR-T cell therapy.

To be eligible for the study, patients had to be between the ages of 16 and 70 years, and they could not have received prior anti-CD20 monoclonal antibody and anthracycline treatment. Patients had to have an ECOG performance status of 0 to 2 with a life expectancy greater than 3 months and adequate organ function to enroll in the study. Patients also had to have measurable disease according to the IWG Response Criteria for Malignant Lymphoma.

Patients who had a CR with no evidence of disease were ineligible to enroll. If they had definite involvement of the gastrointestinal tract, negative tumor puncture detection in both CD19 and CD20, or had serious uncontrolled medical disorders or active infections, they also could not enroll. Patients were also excluded from the study if they were deemed unsuitable for the trial based on clinical judgement or were pregnant or lactating.

CD19-targeted CAR T cells have been highly effective in the treatment landscape of hematologic malignancies, but the recurrence rate appears high, which is a major obstacle to durable remissions with this therapy. This study aimed to evaluate the safety and tolerability of intravenous tandem CD19/20 CAR T cells among patients with relapsed/refractory NHL.

Secondary objectives of this study also included assessment of efficacy of the study treatment defined by ORR and evaluation of the duration of overall response, progression-free and overall survival. An exploratory objective of the study was to determine in vivo expansion and persistence of the Tandem CD19/CD20 CAR T cells.

The rationale for this study was to address the high recurrence rate observed with CAR T-cell therapy, which often prevents durable remission after treatment. Overall the optimized tandem CAR T treatment appeared feasible in patients with B-NHL. Although many of the patients in the study had heavy tumor burden, were in poor physical condition, or had highly aggressive characteristics, they were still able to achieve a satisfactory ORR and CR rate with the tandem CD19/CD20 CAR-engineered T-cell therapy.

Reference

Ja-Jing Z, Yao W, Zhi-Qiang Wu, et al. Safety and Efficacy of Optimized Tandem CD19/CD20 CAR-Engineered T Cells in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 38: 2020 (suppl; abstr 3034). doi: 10.1200/JCO.2020.38.15_suppl.3034

Go here to read the rest:
Optimized Tandem CAR T-Cell Therapy Targeted CD19/CD20 Appears Feasible in B-NHL - Targeted Oncology

ReNeuron encouraged by progress in stroke and RP treatments – Proactive Investors UK

What the company does

Human retinal progenitor cells (hRPC)

Human retinal progenitor cells differentiate into components of the retina.

Reneuron has developed the ability to scale up the manufacturing of hRPCs using a patented low-oxygen cell expansion technology.

The hRPC cell therapy candidate is being evaluated in an ongoing phase I/IIa clinical trial in the US in subjects with a blindness-causing inherited retinal disease, retinitis pigmentosa (RP).

CTX Cells

CTX cell therapy candidate is a treatment for patients left disabled by the effects of a stroke.

Reneurons product is a standardised, clinical and commercial-grade cell therapy product capable of treating all eligible patients presenting with the diseases targeted, without the need for additional immunosuppressive drug treatments.

Data from the Phase II PISCES trial indicated CTX therapy was safe and well-tolerated and produced clinically meaningful and sustained improvement in the level of disability and dependence as well as motor function.

Exosome platform

Exosomes are nanoparticles, released by cells, and contain a number of active proteins and micro RNAs, which are short non-coding RNAs capable of regulating gene expression, that arebelieved to play a key role in cell-to-cell communication.

ExoPr0, Reneurons first CTX-derived exosome therapeutic candidate, has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle

hRPC

's ()human retinal progenitor cells (hRPC) have scored some early success.

A Phase I/II assessment of a very small group of sufferers of a blindness-causing disease called retinitis pigmentosa saw a significant improvement in vision after treatment.

Six months after treatment there was a mean improvement of 18.5per treated eye, with a mean improvement of 12 letters per treated eye after nine months, whereasinexorable disease progression is the norm for this disease.

With a total of 22 patients now treated and the study still ongoing, ReNeuron said the efficacy in subsequent patients was seen but at a lower rate and magnitude, with improvement in visual acuity ranging from +5 to +11 letters in the treated eye threemonths after treatment.

In February, clinicaldata from the PISCES II clinical trial were published in peer-reviewedJournal of Neurology, Neurosurgery, and Psychiatry.

CTX

A peer journal review published in May indicated a CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder.

ReNeuron has previously presented data demonstrating that its CTX stem cell line, currently undergoing clinical evaluation for the treatment of stroke disability, can cause functional and behavioural recovery in animal models of ischemic (restriction of blood supply) injury.

The new data showed that implantation of CTX cells into a model of Huntington's disease can reduce inflammation, glial scar formation and induce host neurogenesis (the generation of new brain cells) leading to a recovery in behavioural deficits.

Coronavirus

In April, Reneuron said it haddeveloped a line of the human exosomes that can deliver a medically relevant payload: Viral vaccines thatmight help in the fight against coronavirus.

The stem cell specialist added that the disruption from lockdowns would inevitably lead to delays in the recruitment of patients for trials of its treatments for stroke disability and retinitis pigmentosa (RP).

It said it will update on how this will affect the release of top-line data from the two studies once it knows the full impact of the restrictions.

More:
ReNeuron encouraged by progress in stroke and RP treatments - Proactive Investors UK

NexImmune to Present at the Jefferies Virtual Healthcare Conference – GlobeNewswire

GAITHERSBURG, Md., June 01, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharma company advancing a new generation of nanoparticle-based therapies for targeted immune system response, today announced thatJohn Trainer, Chief Financial Officer, will present a company overview at theJefferies Virtual Healthcare ConferenceonTuesday, June 2, 2020at3:30 p.m. Eastern time.

About NexImmunes Lead T Cell Therapy Programs

NexImmunes two lead T cell therapy programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy, respectively. The Company expects initial data in the fourth quarter of 2020.The Companys pipeline also consists of four additional preclinical programs, including cell therapy and injectable product candidates for the treatment of oncology, autoimmune diseases, and infectious diseases.

About NexImmune

NexImmune is a Gaithersburg, MD-based clinical-stage biopharma company advancing a new generation of immunotherapies based on its proprietary artificial immune modulation (AIM) technology. The AIM platform is designed to generate a targeted T cell-mediated immune response and is initially being developed as a cell therapy for the treatment of hematologic cancers. AIM nano-particles (AIM-np) act as synthetic dendritic cells to deliver immune-specific signals to targeted T cells and can direct the activation or suppression of cell-mediated immunity. In cancer, AIM-expanded T cells have demonstrated best-in-class anti-tumor properties, including the ability to address key mechanisms of tumor escape and relapse through a unique combination of anti-tumor potency, multi-antigen target-specific killing, and long-term T cell persistence. The modular design of the AIM platform enables rapid expansion across multiple therapeutic areas (autoimmune diseases and infectious diseases), with both cell therapy and injectable products. For more information, visit http://www.neximmune.com.

Media Contact:Mike BeyerSam Brown Inc. Healthcare Communications312-961-2502mikebeyer@sambrown.com

View original post here:
NexImmune to Present at the Jefferies Virtual Healthcare Conference - GlobeNewswire

Global Stem Cell Therapy Market 2020 Research Report Insights and Analysis, Forecast to 2026 – 3rd Watch News

The Stem Cell Therapy market has witnessed growth from USD XX million to USD XX million from 2014 to 2019. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2026.

The report mainly studies the size, recent trends and development status of the Stem Cell Therapy market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Stem Cell Therapy market.

Download PDF Sample of Stem Cell Therapy Market report @ https://www.arcognizance.com/enquiry-sample/1030514

Major Players in the global Stem Cell Therapy market include:, Holostem Terapie Avanzate, Osiris Therapeutics, NuVasive, BIOTIME, Advanced Cell Technology, Caladrius, Pharmicell, JCR Pharmaceuticals, RTI Surgical, AlloSource, MEDIPOST, Anterogen, BrainStorm Cell Therapeutics

On the basis of types, the Stem Cell Therapy market is primarily split into:, Autologous, Allogeneic

On the basis of applications, the market covers:, Musculoskeletal disorders, Wounds and injuries, Cardiovascular diseases, Surgeries, Gastrointestinal diseases, Other applications

Brief about Stem Cell Therapy Market Report with [emailprotected] https://www.arcognizance.com/report/global-stem-cell-therapy-market-report-2019-competitive-landscape-trends-and-opportunities

Geographically, the report includes the research on production, consumption, revenue, market share and growth rate, and forecast (2014-2026) of the following regions:, United States, Europe (Germany, UK, France, Italy, Spain, Russia, Poland), China, Japan, India , Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam), Central and South America (Brazil, Mexico, Colombia), Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria), Other Regions

Chapter 1 provides an overview of Stem Cell Therapy market, containing global revenue, global production, sales, and CAGR. The forecast and analysis of Stem Cell Therapy market by type, application, and region are also presented in this chapter.

Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.

Chapter 3 provides a full-scale analysis of major players in Stem Cell Therapy industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.

Chapter 4 gives a worldwide view of Stem Cell Therapy market. It includes production, market share revenue, price, and the growth rate by type.

Chapter 5 focuses on the application of Stem Cell Therapy, by analyzing the consumption and its growth rate of each application.

Chapter 6 is about production, consumption, export, and import of Stem Cell Therapy in each region.

Chapter 7 pays attention to the production, revenue, price and gross margin of Stem Cell Therapy in markets of different regions. The analysis on production, revenue, price and gross margin of the global market is covered in this part.

Chapter 8 concentrates on manufacturing analysis, including key raw material analysis, cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.

Chapter 9 introduces the industrial chain of Stem Cell Therapy. Industrial chain analysis, raw material sources and downstream buyers are analyzed in this chapter.

Chapter 10 provides clear insights into market dynamics.

Chapter 11 prospects the whole Stem Cell Therapy market, including the global production and revenue forecast, regional forecast. It also foresees the Stem Cell Therapy market by type and application.

Chapter 12 concludes the research findings and refines all the highlights of the study.

Chapter 13 introduces the research methodology and sources of research data for your understanding.

Years considered for this report:, Historical Years: 2014-2018, Base Year: 2019, Estimated Year: 2019, Forecast Period: 2019-2026,

Some Point of Table of Content:

Chapter One: Stem Cell Therapy Market Overview

Chapter Two: Global Stem Cell Therapy Market Landscape by Player

Chapter Three: Players Profiles

Chapter Four: Global Stem Cell Therapy Production, Revenue (Value), Price Trend by Type

Chapter Five: Global Stem Cell Therapy Market Analysis by Application

Chapter Six: Global Stem Cell Therapy Production, Consumption, Export, Import by Region (2014-2019)

Chapter Seven: Global Stem Cell Therapy Production, Revenue (Value) by Region (2014-2019)

Chapter Eight: Stem Cell Therapy Manufacturing Analysis

Chapter Nine: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Stem Cell Therapy Market Forecast (2019-2026)

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Appendix continued

List of tablesList of Tables and FiguresFigure Stem Cell Therapy Product PictureTable Global Stem Cell Therapy Production and CAGR (%) Comparison by TypeTable Profile of AutologousTable Profile of AllogeneicTable Stem Cell Therapy Consumption (Sales) Comparison by Application (2014-2026)Table Profile of Musculoskeletal disordersTable Profile of Wounds and injuriesTable Profile of Cardiovascular diseasesTable Profile of SurgeriesTable Profile of Gastrointestinal diseasesTable Profile of Other applicationsFigure Global Stem Cell Therapy Market Size (Value) and CAGR (%) (2014-2026)Figure United States Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Europe Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Germany Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure UK Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure France Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Italy Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Spain Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Russia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Poland Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure China Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Japan Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure India Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Southeast Asia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Malaysia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Singapore Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Philippines Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Indonesia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Thailand Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Vietnam Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Central and South America Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Brazil Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Mexico Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Colombia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Middle East and Africa Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Saudi Arabia Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure United Arab Emirates Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Turkey Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Egypt Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure South Africa Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Nigeria Stem Cell Therapy Revenue and Growth Rate (2014-2026)Figure Global Stem Cell Therapy Production Status and Outlook (2014-2026)Table Global Stem Cell Therapy Production by Player (2014-2019)Table Global Stem Cell Therapy Production Share by Player (2014-2019)Figure Global Stem Cell Therapy Production Share by Player in 2018Table Stem Cell Therapy Revenue by Player (2014-2019)Table Stem Cell Therapy Revenue Market Share by Player (2014-2019)Table Stem Cell Therapy Price by Player (2014-2019)Table Stem Cell Therapy Manufacturing Base Distribution and Sales Area by PlayerTable Stem Cell Therapy Product Type by PlayerTable Mergers & Acquisitions, Expansion PlansTable Holostem Terapie Avanzate ProfileTable Holostem Terapie Avanzate Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Osiris Therapeutics ProfileTable Osiris Therapeutics Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table NuVasive ProfileTable NuVasive Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table BIOTIME ProfileTable BIOTIME Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Advanced Cell Technology ProfileTable Advanced Cell Technology Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Caladrius ProfileTable Caladrius Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Pharmicell ProfileTable Pharmicell Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table JCR Pharmaceuticals ProfileTable JCR Pharmaceuticals Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table RTI Surgical ProfileTable RTI Surgical Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table AlloSource ProfileTable AlloSource Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table MEDIPOST ProfileTable MEDIPOST Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Anterogen ProfileTable Anterogen Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table BrainStorm Cell Therapeutics ProfileTable BrainStorm Cell Therapeutics Stem Cell Therapy Production, Revenue, Price and Gross Margin (2014-2019)Table Global Stem Cell Therapy Production by Type (2014-2019)Table Global Stem Cell Therapy Production Market Share by Type (2014-2019)Figure Global Stem Cell Therapy Production Market Share by Type in 2018Table Global Stem Cell Therapy Revenue by Type (2014-2019)Table Global Stem Cell Therapy Revenue Market Share by Type (2014-2019)Figure Global Stem Cell Therapy Revenue Market Share by Type in 2018Table Stem Cell Therapy Price by Type (2014-2019)Figure Global Stem Cell Therapy Production Growth Rate of Autologous (2014-2019)Figure Global Stem Cell Therapy Production Growth Rate of Allogeneic (2014-2019)Table Global Stem Cell Therapy Consumption by Application (2014-2019)Table Global Stem Cell Therapy Consumption Market Share by Application (2014-2019)Table Global Stem Cell Therapy Consumption of Musculoskeletal disorders (2014-2019)Table Global Stem Cell Therapy Consumption of Wounds and injuries (2014-2019)Table Global Stem Cell Therapy Consumption of Cardiovascular diseases (2014-2019)Table Global Stem Cell Therapy Consumption of Surgeries (2014-2019)Table Global Stem Cell Therapy Consumption of Gastrointestinal diseases (2014-2019)Table Global Stem Cell Therapy Consumption of Other applications (2014-2019)Table Global Stem Cell Therapy Consumption by Region (2014-2019)Table Global Stem Cell Therapy Consumption Market Share by Region (2014-2019)Table United States Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Europe Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table China Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Japan Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table India Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Southeast Asia Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)Table Central and South America Stem Cell Therapy Production, Consumption, Export, Import (2014-2019)continued

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read this article:
Global Stem Cell Therapy Market 2020 Research Report Insights and Analysis, Forecast to 2026 - 3rd Watch News